[1. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108.10.3322/canjclin.55.2.7415761078]Search in Google Scholar
[2. Hashem B. El-Serag. Hepatocellular Carcinoma. N Engl J Med 2011; 365: 1118–1127 DOI: 10.1056/NEJMra100168310.1056/NEJMra100168321992124]Open DOISearch in Google Scholar
[3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.10.1053/j.gastro.2007.04.06117570226]Search in Google Scholar
[4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology : WJG. 2008; 14(27):4 300–4308. doi:10.3748/wjg.14.4300.10.3748/wjg.14.4300273118018666317]Open DOISearch in Google Scholar
[5. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From Cirrhosis to Hepatocellular Carcinoma: New Molecular In sights on Inflammation and Cellular Senescence. Liver Cancer. 2013; 2(3–4): 367–383. doi:10.1159/000343852.10.1159/000343852388131924400224]Open DOISearch in Google Scholar
[6. Gilgenkrantz H, de l’Hortet AC. New insights into liver regeneration. Clin Res Hepatol Gastroenterol. 2011; 35: 623–9. DOI:10.1016/j.clinre.2011.04.002.10.1016/j.clinre.2011.04.00221613004]Open DOISearch in Google Scholar
[7. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol. 2012; 57: 692–4. DOI:10.1002/hep.20969.10.1002/hep.2096916447274]Open DOISearch in Google Scholar
[8. Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014 Jan; 49(1): 9-23. doi: 10.1007/s00535-013-0907-x.10.1007/s00535-013-0907-x24318021]Open DOISearch in Google Scholar
[9. Gea VH, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144(3): 512–27.10.1053/j.gastro.2013.01.002357806823313965]Search in Google Scholar
[10. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res. 2013; 1(19): 2810–6.10.1158/1078-0432.CCR-12-196123549874]Search in Google Scholar
[11. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013; 2013: 187204.10.1155/2013/187204359118023533994]Search in Google Scholar
[12. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012; 56: 769–75.10.1002/hep.25670408715922378017]Open DOISearch in Google Scholar
[13. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17; 366(1): 2–16.10.1016/j.gene.2005.10.01816377102]Search in Google Scholar
[14. Hirsh FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene2009; 28: S32–S37. Doi:10.1038/onc.2009.199.10.1038/onc.2009.19919680294]Open DOISearch in Google Scholar
[15. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein over-expression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006 Mar 1; 118(5): 1173–80.10.1002/ijc.2145416161046]Search in Google Scholar
[16. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997; 17: 177–82. PMID: 929848710.1111/j.1600-0676.1997.tb00803.x9298487]Search in Google Scholar
[17. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;26(25): 3787–800. DOI: 10.1038/sj.onc.120955610.1038/sj.onc.120955616799620]Open DOISearch in Google Scholar
[18. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193–199. PMID:11925590.10.3748/wjg.v8.i2.193465834911925590]Search in Google Scholar
[19. Zhu AX, Rosmorduc O, Evans J.T.R., Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: A Phase III, Randomized, Double-Blind,Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. J Clin Oncol 2015; 33: 559–566.10.1200/JCO.2013.53.774625547503]Search in Google Scholar
[20. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti K3, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 January; 16(1): 15–31. doi:10.1517/14728222.2011.648617.10.1517/14728222.2011.648617329178722239438]Open DOISearch in Google Scholar
[21. Wu X and Li Y. Signaling Pathways in Liver Cancer, in Alexander Julianov. Liver Tumors. IntechOpen, February 3rd 2012. DOI: 10.5772/31381. Available from: https://www.intechopen.com/books/liver-tumors/signaling-pathways-in-liver-cancer.10.5772/31381.Availablefrom:https://www.intechopen.com/books/liver-tumors/signaling-pathways---]Open DOISearch in Google Scholar
[22. Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, et al. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel). 2011 May 18; 3(2): 2444–61. doi: 10.3390/cancers3022444.10.3390/cancers3022444]Open DOISearch in Google Scholar
[23. Jorissen R.N, Walker F, Pouliot, N, Garrett T.P, Ward C.W, Burgess A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003; 284, 31–53.10.1016/S0014-4827(02)00098-8]Search in Google Scholar
[24. Citri A, Yarden Y. EGF-ErbB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006; 7, 505–516.10.1038/nrm1962]Open DOISearch in Google Scholar
[25. Schneider M.R, Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 2009; 218, 460–466.10.1002/jcp.21635]Search in Google Scholar
[26. Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci. 2015 Dec 29; 17(1). pii: E30. doi: 10.3390/ijms17010030.10.3390/ijms17010030]Open DOISearch in Google Scholar
[27. Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology. 2002; 123: 2017–27.10.1053/gast.2002.37060]Search in Google Scholar
[28. Berasain C, Perugorrıa MJ, Latasa MU, Castillo J, Goni S, Santamaría M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009; 234: 713–25.10.3181/0901-MR-12]Search in Google Scholar
[29. Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000 Jun; 48(6): 821–30. DOI:10.1177/002215540004800610.10.1177/002215540004800610]Open DOISearch in Google Scholar
[30. Qiao Q, Zhang J, Wang W, Li Q. Over expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology. 2008 Jan-Feb; 55(81): 169–72. PMID:18507100.]Search in Google Scholar
[31. Mantovani A, Allavena P, Sica A, BalkwillF. Cancer-related inflammation. Nature 2008; 454: 436–444 doi:10.1038/nature07205.10.1038/07205]Open DOISearch in Google Scholar
[32. Uslu S, Kirimlioglu H, Ince U. Analysis of Epidermal Growth Factor Receptor Expression in Hepatocellular Carcinoma: A Comparision of Fluorescence in Situ Hybridization and Immunochemistry. J Gastroenterol Hepatol Res 2014; 3(8): 1193–1197 URL: http://www.ghrnet.org/index.php/joghr/article/view/815.]Search in Google Scholar
[33. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K et al. Expression and clinical significance of ErbB receptor family in hepatocellular carcinoma. Br. J. Cancer 2001; 84, 1377–1383. DOI:10.1054/bjoc.2000.1580.10.1054/bjoc.2000.1580]Open DOISearch in Google Scholar
[34. Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, et al. Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinogenes. 2003; 36, 130–141. doi.org/10.1002/mc.10103.10.1002/mc.10103]Open DOISearch in Google Scholar
[35. DeCicco LA, Kong J, Ringer DP.Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Lett. 1997 Jan 1; 111(1–2): 149–56.10.1016/S0304-3835(96)04524-7]Search in Google Scholar
[36. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues. BioMed Research International,Volume 2015, Article ID 171845, 7 pages http://dx.doi.org/10.1155/2015/17184510.1155/2015/171845457598526436086]Open DOISearch in Google Scholar
[37. Ali R, Wendt MK. The paradoxa functions of EGFR during breast cancer progression. Signal Transduction and Targeted Therapy, volume 2 Article number: 16042 (2017) doi:10.1038/sigtrans.2016.42.10.1038/sigtrans.2016.42539711928435746]Open DOISearch in Google Scholar
[38. Whittaker S, Marais R, Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010 Sep 9; 29(36): 4989–5005. doi: 10.1038/onc.2010.236. Epub 2010 Jul 19.10.1038/onc.2010.236.Epub2010Jul19]Open DOISearch in Google Scholar
[39. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK.Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1): 15–31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12.10.1517/14728222.2011.648617.Epub201212]Open DOISearch in Google Scholar
[40. Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion. 2017; 96(1): 1-4. doi: 10.1159/000464282. Epub 2017 Jun 13.2860574510.1159/000464282.Epub201713]Search in Google Scholar